/주식/TWST
TWST

TWST

USD

Twist Bioscience Corporation Common Stock

$39.900-0.370 (-0.919%)

실시간 가격

Healthcare
Diagnostics & Research
미국

가격 차트

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$40.270

고가

$41.120

저가

$38.688

거래량

0.14M

기업 기본 정보

시가총액

2.4B

산업

Diagnostics & Research

국가

United States

거래 통계

평균 거래량

1.17M

거래소

NMS

통화

USD

52주 범위

저가 $30.32현재가 $39.900고가 $60.9

AI 분석 리포트

마지막 업데이트: 2025년 4월 22일
AI 생성데이터 소스: Yahoo Finance, Bloomberg, SEC

TWST (Twist Bioscience Corporation Common Stock): What's Happening and What to Watch

Stock Symbol: TWST Generate Date: 2025-04-22 20:53:32

Alright, let's break down what's been going on with Twist Bioscience stock and what the tea leaves might be suggesting. We'll look at the latest news, how the price has been acting, and what some of the automated tools are predicting.

The Latest News Buzz

So, the main piece of news we've got is from Barclays, a pretty big bank. Their analyst, Luke Sergott, still thinks Twist Bioscience is a stock you should probably hold onto – they kept their "Overweight" rating. That's generally a good sign; it means they see potential here.

But, and this is a key point, they did lower their price target. They used to think the stock could hit $58, but now they're saying $45. What does that tell us? It's a bit of a mixed signal. They haven't given up on the company, which is positive. However, they're less optimistic about just how much it's likely to climb in the near future. Think of it like a coach still believing in the team but maybe adjusting their expectations for the next few games.

Checking the Price Action

Looking at the stock's journey over the past couple of months, it's been quite a ride. Back in late January and early February, shares were trading up in the $50-$55 range. Things took a noticeable dip through February and into early March, dropping into the high $30s and low $40s. March saw a bit of a bounce, getting back into the mid-$40s briefly.

More recently, in April, we saw another slide, with the price hitting lows around $33-$34. As of the last data point (April 22nd), the stock closed around $36.94. So, the overall trend from the start of the year has been downwards, but it seems to have found some sort of floor in the mid-$30s lately.

Now, let's peek at what the AI prediction model is saying for the very short term. It predicts the price will be essentially flat today (0.0% change), but then sees a potential upward move of about 4% tomorrow and another 4% the day after. That suggests the AI thinks this recent stability in the mid-$30s could be a springboard for a small bounce.

Putting It All Together: What Might Be Next?

Based on the news, the recent price moves, and the AI's short-term forecast, here's one way to look at it:

The analyst still likes the stock overall, even with a lower target. The price has taken a hit but seems to be trying to stabilize around the mid-$30s. The AI model is actually predicting a small upward push from here in the next couple of days.

This combination might suggest a cautiously positive leaning for the very near term. It doesn't scream "buy everything now," but it doesn't necessarily say "run for the hills" either.

  • Potential Entry Consideration: If you were thinking about this stock, the current price area in the mid-$30s, especially if it dips back towards those recent lows around $34, could be a point of interest. This aligns with where the AI sees a potential bounce starting.
  • Potential Exit/Stop-Loss Consideration: Managing risk is always smart. The recommendation data points to $31.08 as a potential stop-loss level. This is below the recent lows and could be a place to consider cutting losses if the price breaks down significantly. For taking profits, the analyst's new target of $45 is out there as a longer-term goal. For the very short term, if the AI's prediction plays out, you might look for a move towards the upper end of the recent range, perhaps the low $40s, but that's just speculation based on past volatility.

A Little Company Context

Remember, Twist Bioscience is in the Healthcare sector, specifically Diagnostics & Research. They make synthetic DNA products. This is a high-tech, often volatile space. The company isn't profitable yet (that's what the negative P/E ratio tells us), which is common for growth companies in this field, but it means their stock price can react strongly to news about their technology, sales, or the broader biotech market. They're a mid-size company with a market cap around $2.3 billion.

Important Disclaimer: This analysis is purely for informational purposes based on the provided data. It's not financial advice. Stock markets are risky, and prices can go down as well as up. Always do your own thorough research or talk to a qualified financial advisor before making any investment decisions.

관련 뉴스

BusinessWire

Twist Bioscience Expands Universal Adapter Portfolio with Launch of High Throughput UDI Adapter System

Adds to robust offering of NGS tools enabling exome sequencing, whole genome sequencing, RNA sequencing, deep sequencing for liquid biopsy research and MRD, and methylation detection Diverse portfolio of adapter sets

더 보기
Twist Bioscience Expands Universal Adapter Portfolio with Launch of High Throughput UDI Adapter System
Analyst Upgrades

Barclays Maintains Overweight on Twist Bioscience, Lowers Price Target to $45

Barclays analyst Luke Sergott maintains Twist Bioscience with a Overweight and lowers the price target from $58 to $45.

더 보기
Barclays Maintains Overweight on Twist Bioscience, Lowers Price Target to $45

AI 예측Beta

AI 추천

강세

업데이트 시간: 2025년 4월 29일 오전 08:43

약세중립강세

64.7% 신뢰도

리스크 & 트레이딩

리스크 수준3/5
중위험
적합 대상
성장공격적가치
트레이딩 가이드

진입점

$39.40

익절

$43.80

손절

$35.87

핵심 요소

RSI 72.7은(는) 과매수 상태를 나타냅니다.
PDI 15.6이(가) ADX 29.3과 함께 MDI 5.8 위에 있어 강세 추세를 시사합니다.
거래량은 평균(12,819)의 4.6배로 극도로 강력한 매수 압력을 나타냅니다.
MACD 0.2238이(가) 신호선 0.1350 위에 있어 강세 교차를 나타냅니다.

최신 정보 받기

가격 알림 설정, AI 분석 업데이트 및 실시간 시장 뉴스 받기